Sugi Predict

Sugi Predict / Targets / BRWD1

BRWD1

Bromodomain and WD repeat-containing protein 1 · Q9NSI6 · BRWD1 on Sugi Atlas →

4,196 patent compounds predicted against BRWD1, 3,658 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1906368 SCHEMBL1906368 1.00 1/20
SCHEMBL1907498 SCHEMBL1907498 1.00 1/20
SCHEMBL221384 SCHEMBL221384 0.85 1/20
SCHEMBL223735 SCHEMBL223735 0.85 1/20
SCHEMBL11907473 SCHEMBL11907473 0.84 1/20
SCHEMBL1902031 SCHEMBL1902031 0.83 1/20
SCHEMBL8225867 SCHEMBL8225867 0.82 1/20
SCHEMBL11907555 SCHEMBL11907555 0.81 1/20
SCHEMBL11907612 SCHEMBL11907612 0.78 1/20
SCHEMBL1903230 SCHEMBL1903230 0.78 1/20
SCHEMBL1904822 SCHEMBL1904822 0.78 1/20
SCHEMBL1905787 SCHEMBL1905787 0.78 1/20
SCHEMBL5836486 SCHEMBL5836486 0.77 1/20
SCHEMBL5836491 SCHEMBL5836491 0.77 1/20
SCHEMBL5836493 SCHEMBL5836493 0.77 1/20
SCHEMBL1902624 SCHEMBL1902624 0.77 1/20
SCHEMBL11908462 SCHEMBL11908462 0.77 1/20
SCHEMBL2741210 SCHEMBL2741210 0.76 1/20
SCHEMBL5837528 SCHEMBL5837528 0.75 1/20
SCHEMBL5837533 SCHEMBL5837533 0.75 1/20

Clinical trials — most relevant to BRWD1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma PHASE1/PHASE2RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of BR3005 and Co-administration of BR3005-1 and BR3005-2 Under Fed Conditions in Healthy Adult Volunteers PHASE1COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer PHASE1SUSPENDED
Better Delineation of BCL11B Related Phenotype and Epigenetic Signature. nanCOMPLETED
Application of Linkage Analysis in the Identification of Novel Hereditary Factors in Familial Aneurysms nanACTIVE_NOT_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Shwachman Diamond Syndrome Registry and Study nanRECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Molecular Diagnosis of Syndromic or Isolated Severe Intellectual Disability Using Whole Exome Sequencing : a Pilot Study nanCOMPLETED
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions nanCOMPLETED
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD) nanCOMPLETED
The Belgian Genome Resource to Resolve Rare Diseases nanCOMPLETED
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN
Familial Investigations of Childhood Cancer Predisposition nanRECRUITING
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a BRWD1 binder may also engage these)

ProteinNameSimilarity
Q921C3 — 1.000 Q921C3 →
Q6RI45 — 1.000 Q6RI45 →
A2AHJ4 — 0.999 A2AHJ4 →
Q8VDD9 — 0.998 Q8VDD9 →
Q8C0M0 — 0.990 Q8C0M0 →
Q8WWQ0 — 0.989 Q8WWQ0 →
Q5ZLG9 — 0.987 Q5ZLG9 →
A0JMR6 — 0.987 A0JMR6 →
Q812E4 — 0.986 Q812E4 →
F1ND48 — 0.986 F1ND48 →
Q8VDY4 — 0.986 Q8VDY4 →
P31266 — 0.986 P31266 →
EEF2K Eukaryotic elongation factor 2 kinase 0.986 landscape →
E1BTG2 — 0.986 E1BTG2 →
Q7ZXX9 — 0.985 Q7ZXX9 →
Q5RHQ8 — 0.985 Q5RHQ8 →
Q8TDW5 — 0.985 Q8TDW5 →
Q86UW7 — 0.985 Q86UW7 →
Q69ZX6 — 0.984 Q69ZX6 →
O15259 — 0.984 O15259 →
Q8BYR5 — 0.984 Q8BYR5 →
Q8BMA3 — 0.984 Q8BMA3 →
Q498F0 — 0.984 Q498F0 →
Q0P410 — 0.984 Q0P410 →
Q7T0W1 — 0.984 Q7T0W1 →
P70531 — 0.983 P70531 →
O95876 — 0.983 O95876 →
Q9P203 — 0.983 Q9P203 →
Q3SXY8 — 0.983 Q3SXY8 →
MAP3K5 Mitogen-activated protein kinase kinase kinase 5 0.983 landscape →